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Abstract: Mucositis is a common side-effect of chemotherapy treatment, inducing alterations in
the composition of the gut microbiota. Redox active compounds, such as vitamins B2 and C,
have been shown to reduce inflammation and enhance the growth of anaerobic bacteria in the gut.
We therefore aimed to (1) validate the ability of these compounds to promote bacterial cell growth
in vitro, and (2) determine their prophylactic efficacy in a rat model of methotrexate (MTX)-induced
mucositis. Bacterial growth curves were performed to assess the growth kinetics of bacteria exposed
to Vitamins C and B2 (0.5 mM). Male wistar rats (150–200 g) received vitamins B2 (12 mg/day) and C
(50 mg/day) via daily oral gavage (from day −1 to day 10). MTX (45 mg/Kg) was administrated
via I.V. injection (N = 4–8/group) on day 0. Body weight, water/food consumption and diarrhea
were assessed daily. Blood and faecal samples were collected longitudinally to assess citrulline levels
(mucositis biomarker) and gut microbiota composition. Vitamins C/B2 enhanced the in vitro growth
of anaerobic bacteria Blautia coccoides and Roseburia intestinalis. Contrarily to vitamin B2, in vivo
administration of Vitamin C significantly attenuated clinical symptoms of mucositis. Despite their
influence on the composition of the gut microbiota, both vitamins did not modulate the course of
MTX-induced mucositis, as accessed by plasma citrulline. Vitamins B2 and C enhanced anaerobic
bacterial growth in vitro, however their ability to mitigate MTX-induced mucositis was limited.
Keywords: chemotherapy-induced mucositis; methotrexate; gut microbiota; anaerobic bacteria;
vitamin C; vitamin B2
1. Introduction
Gastrointestinal mucositis is one of the most common and clinically significant side
effects of anticancer therapy [1,2]. Patients undergoing chemotherapy present with a
spectrum of complications to mucositis, including nausea/vomiting, diarrhea, abdominal
pain, infection and malnutrition. These symptoms require significant supportive care
interventions, leading to longer hospitalization, thus impacting the patient’s quality of
life. In severe cases, chemotherapy dose reductions or complete cessation of treatment are
required, compromising the survival of patients [1].
Gastrointestinal mucositis is initiated by direct cytotoxic injury to highly proliferative
intestinal stem cells, exacerbated by a secondary wave of indirect injury mediated by
innate immune activation, aberrant inflammatory signaling and microbial disruption [3].
While a large number of studies have demonstrated benefits of targeting each of these
specific mechanisms, few of these have translated clinically, presumably due to the nar-
row spectrum of disease mechanisms being targeted. In contrast to existing approaches,
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vitamins present as an easy and encouraging prophylactic approach due to their ability to
simultaneously modulate multiple aspects of mucositis pathogenesis, including oxidative
stress, inflammation and microbial disruption [4–6].
Vitamins C and B2 are essential nutrients for a normal metabolism. The recommended
daily dose of vitamin C for an adult male is 90mg, whereas vitamin B2 is 1.3 mg [7].
Vitamins C and B2 are of particular interest due to the increased evidence supportingtheir
immunomodulatory properties and the impact on the microbiota, particularly under
oxidative stress [8–11]. In animal models of colitis, these vitamins were shown not only
to ameliorate symptoms but also to enhance the growth of commensal bacteria in the gut
such as Lactobacillus plantarum [12–14]. In the setting of mucositis, multivitamin use prior
to therapy has been reported as a modulator of mucositis outcome, providing protection to
stem cell transplantation recipients [15]. Similarly, vitamin C has been shown to attenuate
5-fluorouracil-induced gastrointestinal mucositis by inhibiting the activation of the NF-κB
pathway and by reducing lipid peroxidation and myeloperoxidase (MPO) [8].
Vitamin B2, or riboflavin, has been most extensively characterized for its impact on
the microbiota. While not directly assessed in the setting of mucositis, Faecalibacterium
prausnitzii—a key butyrate producer with reduced abundance following chemotherapy—is
particularly dependent on vitamin B2 as a redox mediator for extracellular electron transfer,
thus reducing oxidative stress which highlights the potential of vitamin B2 in mucositis
prevention [9]. The current study therefore aimed to (1) evaluate the impact of vitamin C
and B2 on the growth properties in vitro of bacterial strains that are frequently associated
with dysbiosis during chemotherapy-induced mucositis, and (2) evaluate their prophylactic
efficacy in a validated preclinical model of methotrexate-induced gastrointestinal mucositis.
2. Materials and Methods
2.1. Bacterial Strains and Culturing Conditions
Blautia coccoides, Roseburia intestinalis, Enterococcus faecalis and Escherichia coli were
isolated from faecal samples collected from Wistar rats and identified by Sanger sequencing
of the 16S rRNA-gene [16,17]. Bacteria were isolated from rat faecal samples at 37 ◦C on
yeast extract, casitone, fatty acid and glucose (YCFAG) agar under anaerobic conditions [18].
The strains were grown in YCFAG broth to an optical density at 600 nm (OD600) of 0.8.
Bacteria were stored in YCFAG containing 20% glycerol at −80 ◦C prior to use in the assays.
2.2. Bacterial Growth Experiments
For growth experiments, a bacterial overnight culture was added to 100 µL of YCFAG
supplemented with 0.5 mM of vitamin B2 or vitamin C, or both, to an OD600 of 0.05.
To create a semi-anaerobic environment, cell suspensions were plated in 96 well plates and
properly sealed with a plate sealer inside the anaerobic cabinet (nitrogen (90%), hydrogen
(5%) and COs (5%)). The sealer tape allowed penetration of low amounts of oxygen.
The plate was transferred to a Biotek Synergy 2 system in which growth curves were
measured under static conditions at 37 ◦C and an OD of 600 nm measured every 4 h for
48 h. Each growth curve represented the average for three biological replicates.
2.3. Materials
Methotrexate (MTX) was used as a representative anticancer therapy. MTX (50 mg/kg)
was obtained from Pharmachemie Holding B.V. (Haarlem, The Netherlands). The dose of
MTX (45 mg/kg) administrated to the animals was based on previous studies performed
in our lab [19]. Vitamin C (L-ascorbic acid; A0278-25G) and Vitamin B2 (Riboflavin;
R4500-25G) were obtained from Sigma-Aldrich (Schnelldorf, Germany).
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2.4. Animals and Ethics
This study was performed according the ARRIVE guidelines for the accurate and
reproducible reporting of animal research.
2.5. Ethical Statement and Husbandry Specifications
The experimental protocol was approved under number 15338-01-004 by the Ethics
Committee for Animal Experiments, Faculty of Medical Sciences, University of Groningen,
The Netherlands. Male Wistar outbred rats (6–8 weeks old, 100–120 g) were obtained
from Harlan (Horst, The Netherlands). Animals were individually housed in conventional,
plexiglass cages (42.5 × 26.6 × 18.5 cm) at the Central Animal Facilities, University Medical
Center Groningen. Temperature was controlled (21 ± 1 ◦C) with a relative humidity of
55 ± 10% in 12:12-h light-dark cycle (lights on 7 a.m.–7 p.m.). Autoclaved AIN93 G rodent
diet was obtained from Research Diet Services (Wijk bij Duurstede, The Netherlands)
(6.3 mg vitamin B2 and no vitamin C addition) and sterile water were available ad libitum.
Sawdust bedding was provided in all cases, as well as toilet rolls for enrichment. All cages
were randomly arranged across racks to prevent potential biases.
2.6. Experimental Procedures
Forty-four rats were injected intravenously at day 0 with MTX (45 mg/Kg; N = 20)
or with saline solution (0.9%, N = 24), under 3% isoflurane anesthesia as previously
reported [20–22]. Assignment of rats was performed randomly prior to any treatment with
mild adjustments made to ensure comparable baseline body weight. Rats were treated with
either sterile water, vitamin C (50 mg/day) or vitamin B2 (12 mg/day) via oral gavage every
day, starting one day before MTX injection (Figure 1). At day 10, all animals were sacrificed
via isoflurane anesthesia and cervical dislocation. The primary outcome of the study was
gastrointestinal toxicity, defined by plasma citrulline levels. Secondary outcomes included
food intake, body weight, water intake and presence of diarrhea (present as watery diarrhea
or completely absent) were recorded daily. Contrarily vitamin C, in which optimal dose was
calculated according to previous studies, no similar studies with vitamin B2 in rats have
been done [8]. This has led us to first test different doses of vitamin B2: 8, 24 and 48 mg/kg.
For each of these doses, 4 animals were included in the group (data not shown). Since
none of the doses resulted in gut toxicity, we included the results obtained for 48 mg/kg
(12 mg/day). This optimization, together with ethical issues associated with the number of
animals used, resulted in a lower number of animals in the MTX+VitB2 group.
2.7. Plasma Citrulline Levels Determination
The primary outcome of this study was plasma citrulline concentration. Plasma
citrulline is an indicator of small enterocyte mass and a validated biomarker of mucosal
injury [22]. Repeated blood samples (75 µL) were collected from the tail vein into EDTA-
treated hematocrit capillary tubes. Citrulline was determined in 30 µL of plasma (isolated
from whole blood via centrifugation at 4000× g for 10 min) using automated ion-exchange
column chromatography as previously described [22,23].
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Figure 1. The experimental approach. 8-week-old Wistar male rats were orally gavaged with 50 mg/day vitamin C (N = 16)
or 12 mg/day Vitamin B2 (N = 12) every day starting one day before methotrexate (MTX) injection. At days 0, 2, 4, 6 and
10, blood and fecal samples were collected and stored for analysis. At day 10, rats (N = 43) were sacrificed. † At day 3,
one animal from MTX+VitB2 group was sacrificed due to severe symptoms. Blood and fecal samples from this animal were
collected and results included at day 4.
2.8. Microbiome Analysis
2.8.1. DNA Extraction
DNA was extracted from faecal samples using the double bead-beater procedure
adapted from Yu and Morrison (2004) and QIAamp DNA Stool Minikit guidelines (Qiagen,
Hilden, Germany). Briefly, 0.25 g stool was homogenized in 1 mL lysis buffer, containing
500 mM NaCl, 50 mM Tris-HCl (pH 8), 50 mM EDTA, 4% SDS, with 0.5 g 0.1 mm zirconia
beads and four 3 mm glass beads. The faecal homogenate was then heated at 95 ◦C for
15 min, mixing every 5 min, before being centrifuged at 4 ◦C for 5 min (12,000–14,000 rpm).
The supernatant was collected and set aside, and the procedure repeated for the pelleted
stool. Nucleic acids were then purified using selective precipitation of cell debris with
260 µL 10 M ammonium acetate. Samples were incubated on ice for 5 min, before being
centrifuged at 4 ◦C for 10 min (12,000–14,000 rpm). The supernatant was collected and the
pellet discarded, and the procedure repeated. One volume of ice-cold isopropanol was
added to the supernatant and the samples were incubated on ice for 30 min. Nucleic acids
were pelleted by centrifugation (15 min, room temperature), washed with 70% ethanol
and allowed to dry for 5 min at room temperature. Nucleic acids were dissolved in AE
buffer (10 mM Tris-Cl; 0.5 mM EDTA; pH 9.0) and stored at 4 ◦C overnight. The following
day, samples were incubated with 2 µL (10 mg/mL) DNase-free RNase and incubated at
37 ◦C for 15 min. Proteinase K and buffer AL (Qiagen Minikit products) were added and
samples were incubated at 70 ◦C for 10 min. DNA was then transferred to the QIAmp
column and wash steps were performed as per the manufacturer’s guidelines. The final
DNA was eluted in AE buffer and yield/quality was quantified using a NanoDrop UV
Visible Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).
2.8.2. PCR Amplification of V3 and V4 Region of the 16S rRNA Gene
Samples were diluted to 100 ng/µL for all PCR amplification procedures. Each PCR
reaction contained 1 µL of 10 µM 341f forward primer, 25 µL Phire HS II Master Mix, 22 µL
DNase free water, 1 µL of 10 µM 806r barcoded reverse primer and 1 µL DNA template
(100 ng/µL). The sequence of the primers used in this study is listed in Supplementary
Table S1. These were denatured at 98 ◦C for 30 s, and amplified over 31 cycles of 98 ◦C for
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5 s, 50 ◦C for 5 s, and 72 ◦C for 10 s. Samples were held at 72 ◦C for 1 min and kept at 4 ◦C
until collection. Amplification was confirmed using gel electrophoresis.
2.8.3. PCR Purification, Library Preparation and Illumina Sequencing
Size selection and fragment removal was achieved using AMPure XP beads which
were added at a 1:2 ratio to the PCR product. DNA was eluted in 52.5 µL 10 mM Tris
HCL (pH 8.5) and quantified using the Qubit quantification kit (Thermo Fisher Scien-
tific, Waltham, MA, USA) and the Qubit®2.0 Fluorometer (Thermo Fisher Scientific,
Waltham, MA, USA). DNA was diluted to a working concentration of 2 mM and 5 µL
of each sample was pooled to form a single library and stored at −20 ◦C until sequenc-
ing. Sequencing was performed using the MiSeq Benchtop Next Generation Sequencer
(Illumina, San Diego, CA, USA) following the manufacturer’s guidelines.
2.8.4. Statistical Analysis and Bioinformatics
All data sets were assessed for normality using D’Agostino and Pearson and Kolmo
gorov-Smirnov analyses using GraphPad Prism version 8. If normality was confirmed,
data were analyzed using a mixed-effect model with Tukey’s post-hoc testing for multiple
comparisons. In cases where normality was not achieved, a non-parametric Friedman’s test
with Dunn’s post-hoc testing for multiple comparisons was used to determine significance.
16S rRNA sequencing analysis was performed using Qiagen CLC genomics workbench,
kindly provided by Dr. Hannah Wardill. The calculation of alpha diversity (Shannon
index) and OTUs were performed using CLC Microbial Genomic Module package on the
taxonomic level of genera. β-diversity was presented using principal coordinates analysis
(PCoA). PERMANOVA analysis (based on Bray–Curtis dissimilarity) was used to measure
effect size and significance on β-diversity for grouping variables. Bonferroni-corrected
p-values (which correct for multiple testing) were presented in this study. In all cases,
p < 0.05 was considered statistically significant. Statistical analyses for all data sets are
outlined in figure legends.
3. Results
3.1. In Vitro Findings
Vitamins C and B2 Enhance Growth of Anaerobic Bacteria under Oxidative Stress
We selected B. coccoides and R. intestinalis (as members of Lachnospiraceae) due to their
beneficial role in the gut, such as the production of SCFAs [24–26]. Since Enterobacteri-
aceae and enterococci are often associated to a dysbiotic gut, we selected E. faecalis and
E. coli as reference members [21,27]. Under mild oxidative conditions, supplementation
of B. coccoides, R. intestinalis and E. faecalis with 0.5 mM of vitamin C and 0.5 mM of vita-
min B2, alone or in combination, enhanced their growth when compared to the control
(Figure 2). Supplementation of B. coccoides with either vitamin B2 alone (p = 0.0004) or
the combination of both vitamins (p < 0.0001) resulted in significant growth after 24 h of
incubation, when compared to the control group (Figure 2A,B). R. intestinalis growth was
less significant when compared to B. coccoides (Figure 2C). Nevertheless, supplementation
of this bacterium with vitamin C (p = 0.0226), vitamin B2 (p = 0.0011) or both (p = 0.0051)
resulted in significant increase at 24 h (Figure 2D). E. coli growth was not increased after
24 h of incubation when stimulated by these vitamins, whereas E. faecalis was positively
influenced after 24 h of incubation but only when one of the vitamins was added and not
with both (p = 0.0130; p = 0.002) (Figure 2E,F).
3.2. In Vivo Findings
3.2.1. Baseline Data
In accordance with the ARRIVE guidelines, baseline characteristics of all experimental
groups were analysed at day −1, prior to vitamin supplementation (Table 1). No statistical
differences were observed in body weight and plasma citrulline between the different groups.
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Figure 2. The effect of vitamins B2 and C on the growth of B. coccoides (A,B), R. intestinalis (C,D), E. coli
(E,F) and E. faecalis (G,H). Bacteria stimulated with 5 mM of vitamin C and vitamin B2, alone or in
combination, were grown under oxidative conditions for 48 h. Optical density measurements (600 nm)
at 0, 24 and 48 h of incubation (A,C,E,F) and changes between groups were represented separately
after 48 h of incubation (B,D,F,H). All data are presented as mean ± SEM. * (p < 0.05), ** (p < 0.01),
*** (p < 0.001) and **** (p < 0.0001) represent the significant changes between non-supplemented
bacteria (control) and supplemented bacteria (N = 3).
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Table 1. Baseline body weight in each experimental group (mean ± SEM). Animals were randomized
according to the body weight and plasma citrulline levels.
Baseline Body Weight in Each Experiments Group
Body Weight (g) Plasma Citrulline (µmol/L)
Control (N = 8) 95.88 ± 0.22 101.16 ± 4.51
Vitamin C (N = 8) 96.34 ± 0.27 88.52 ± 2.53
Vitamin B2 (N = 8) 95.88 ± 0.22 90.29 ± 9.34
MTX (N = 8) 96.39 ± 0.34 98.33 ± 9.59
MTX+VitC (N = 8) 97.40 ± 0.38 100.05 ± 1.99
MTX+VitB2 (N = 4) 97.82 ± 0.88 104.70 ± 13.84
3.2.2. Vitamin C but Not Vitamin B2 Promotes Body Weight and Food Intake during
MTX-Induced Mucositis
MTX induced a typical clinical phenotype of mucositis which peaked at day 4. Mucositis
was characterized by alterations in body weight (−2.056± 0.54% vs. 14.74 ± 1.22%, p < 0.0001),
food intake (2.71 ± 1.38 vs. 19.36 ± 1.64 g, respectively; p = 0.0001) and plasma citrulline
(14.11 ± 2.86 vs. 88.04 ± 4.02 µmol/L, respectively; p < 0.0001), when compared to vehicle
control animals (Figures 3 and 4).
Figure 3. Effects of vitamin C (50 mg/day/rat) on the clinical parameters. (A) Bodyweight relative
to weight at day 0, which was set at 100%. (B) Food intake in grams per day. (C) Water intake in ml
per day. (D) Plasma citrulline level (µmol/L) measured at days 0, 2, 4, 6 and 10 after MTX injection.
All data are presented as mean ± SEM. # (p < 0.05) and ## (p < 0.01) represent the differences between
the control group and vitamin C-supplemented rats. * (p < 0.05) represent the significant changes
between MTX-treated rats supplemented with vitamin C and MTX-treated rats only.
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Figure 4. Effects of vitamin B2 (12 mg/day/rat) on the clinical parameters. (A) Bodyweight relative
to weight at day 0, which was set at 100%. (B) Food intake in grams per day. (C) Water intake in ml
per day. (D) Plasma citrulline level (µmol/L) measured at days 0, 2, 4, 6 and 10 after MTX injection.
All data are presented as mean ± SEM.
Continuous supplementation with 50 mg/day of vitamin C in healthy rats significantly
increased body weight compared to controls, as observed at day 10 (55.36 ± 3.35% vs.
40.83 ± 2.09% g, respectively, p = 0.018; Figure 3A). However, it did not impact food intake,
water intake or plasma citrulline concentrations (Figure 3B–D).
In MTX-treated rats, vitamin C supplementation attenuated weight loss induced by
MTX on day 4 (3.09 ± 1.68% vs. −2.056 ± 0.54%, p = 0.044) and day 5 (5.066 ± 2.38% vs.
−2.77 ± 1.23%, p = 0.004; Figure 3A). Food intake was also increased in these animals
compared to MTX alone on day 3 (6.63 ± 1.32 vs. 2.66 ± 0.55 g; p = 0.015) and day 4
(9.11 ± 1.81 vs. 2.71 ± 1.39 g; p = 0.014; Figure 3B). No significant effect was observed in
water intake or plasma citrulline (Figure 3C,D). Vitamin B2 did not influence any outcome
measures assessed in both healthy and MTX-treated animals (Figure 4). Treatment with
vitamins, MTX or the combination of both did not cause diarrhea to the animals. Severe
diarrhea, together with weight loss (>20% of the initial weight), was only observed in one
rat (MTX+VitB2) that was sacrificed at day 3, leaving a total of N = 3 in this group. Blood
and fecal samples from this animal were collected and results included at day 4.
3.2.3. Vitamins Fail to Modulate MTX-Induced Microbial Disruption
16S rRNA gene analysis was performed in repeated faecal samples collected longi-
tudinally from N = 8 per group, with exception of MTX+VitB2 animals (N = 4), at days
0, 4 and 10. The number of reads of the sequenced samples are listed in Supplementary
Materials (Table S2). MTX treatment caused gradual reduction in both alpha diversity
(Shannon index) and richness (OTUs) when compared to controls (p = 0.0009 and p = 0.026,
Figure 5). This effect is more pronounced at day 10, where MTX-treated rats present a
significant lower OTUs, when compared to the control group (p = 0.0333, Figure 5A,C).
Continuous supplementation with vitamin C in MTX-treated animals failed to prevent this
decrease in microbial richness (p = 0.0196, Figure 5A). In contrast, vitamin B2 did not have
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any influence on microbial diversity or richness in healthy controls. However, it was able
to mitigate MTX-induced changes in both alpha diversity and OTUs at day 10 (p = 0.0342,
p = 0.0492; Figure 5C,D).
Figure 5. Dynamics of microbial composition defined as alpha-diversity (Shannon) and operational taxonomic unit (OTUs)
by day of treatment. OTUs and alpha-diversity from health and MTX-treated rats supplemented with vitamin C represented
by (A,B) and with vitamin B2 by (C,D). All data are presented as mean ± SEM. # (p < 0.05) and ### (p < 0.001) represent the
significant differences within a group throughout time. * (p < 0.05) represent the significant differences between MTX-treated
and MTX and vitamin B2-treated rats.
3.2.4. Vitamin C Supplementation in MTX-Treated Rats Increases Enterobacteriaceae Family
at Day 4
PERMANOVA analysis (based on Bray–Curtis dissimilarity) confirmed a separation
of samples according to the MTX treatment (p = 0.00001, Figure 6). However, vitamin C
(p = 0.13121) and vitamin B2 (p = 0.1212) treatment did not cause any significant alteration
at day 4 after the MTX treatment. Moreover, no differences in the clustering pattern
between vitamin C and vitamin B2 groups were observed (p = 0.3408).
Relative abundance (taxonomic level family) showed that the compositional differ-
ences at day 4 were driven by losses in Lactobaciliaceae with paralleled increases in Enter-
obacteriaceae, which were more profound in MTX+VitC treated rats (p = 0.0235; p = 0.0296;
Figure 7A,B). These alterations were most likely driven by a gradual reduction in Lactobacil-
lus johnsonii accompanied by an increase of Escherichia coli at day 4 (Figure 7C,D).
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Figure 6. Bacterial profile between different interventions at day 4, after MTX insult. (A) PCoA plot of microbial composition
(Bray–Curtis dissimilarity on taxomomic level of genera) after vitamin C supplementation. (B) PCoA plot after vitamin B2
supplementation.
Figure 7. Relative abundance between healthy controls and MTX-treated and MTX and Vitamin
C-treated rats at day 4 after MTX insult. Relative abundance of Lactobaciliaceae (A), Enterobacteriaceae
(B), Lactobacillus johnsonii (C) and Escherichia coli (D). Relative abundance of Lactobacillus johnsonii
and Escherichia coli were calculated as arcsin sqrt. * (p < 0.05) and ** (p < 0.01) represent the significant
changes in the relative abundance between the different groups.
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3.2.5. Vitamin B2 Induced Changes in the Composition of the Gut Microbiota during
Recovery of MTX-Induced Mucositis
Similar to vitamin C, the effects of vitamin B2 were analysed through principal com-
ponents analysis at day 4. Results showed no significant changes between MTX and
MTX+VitB2 groups (p = 0.1212; Figure 6). At day 4 post-MTX, Vitamin B2 had influence
on the composition of the gut microbiota, with changes in the relative abundance of Ru-
minococcaceae (p = 0.0097) and Muribaculaceae S24-7 (p = 0.0422), when compared to the
MTX control group, (Figure 8A–C). Specifically, a significant increase was observed in
the relative abundance of Ruminococcus bromii in MTX+VitB2, when compared to controls
(p < 0.0001; Figure 8D).
Figure 8. Relative abundance between healthy controls and MTX-treated and MTX and Vitamin
B2-treated rats at day 4 after MTX insult. Relative abundance of Lactobaciliaceae (A), Muribaculaceae
S24-7 (B), Ruminoccoceae (C) and Ruminococcus bromii (D). Relative abundance of Lactobacillus johnsonii
and Escherichia coli were calculated as arcsin sqrt. * (p < 0.05), **(p < 0.01) and **** (p < 0.0001) represent
the significant changes in the relative abundance between the different groups.
4. Discussion
In this study we demonstrate that prophylactic treatment with vitamin C mitigates
the clinical symptoms of MTX-induced mucositis, partially controlling the clinical sympto-
mology of MTX-induced gastrointestinal mucositis such as body weight loss and reduced
food intake. In contrast, vitamin B2 was unable to protect against MTX-induced mucositis
and in discrete cases, worsened the severity of injury. In both cases, vitamin interventions
were unable to modulate the course of MTX-induced mucosal injury, determined by cit-
rulline, despite their influence on microbial composition/integrity demonstrated in vitro
and in vivo.
Our understanding of gastrointestinal mucositis has grown enormously over the past
few decades, with an increasingly sophisticated pathobiological model describing key
events that drive tissue injury and symptoms [28]. Evidence now supports the role of
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host-microbe interactions in the development of mucositis with changes in the composi-
tion of the gut microbiota well documented to coincide with the development of severe
mucositis [21,29]. Similarly, augmentation of the microbiota prior to therapy has been
shown to modulate the course of mucositis, aligning with new research that points to
unique microbial phenotypes that govern mucositis risk [30]. Despite this new insight,
our ability to modulate the microbiota in a way that prevents mucositis remains a challenge,
with probiotics failing to translate clinically [28,31–33]. These underwhelming outcomes
suggest that targeting only the microbiota is not sufficient to overcome the intensity of
injury caused by chemotherapy and interventions that target multiple disease pathways
are of increasing relevance.
Vitamins offer a simple method of targeting microbial and inflammatory mechanisms
driving mucositis, with efficacy demonstrated in models of 5-FU mucositis and other
benign inflammatory conditions [8,34]. In this study, we focus on two different vitamins:
C and B2. Vitamin C is an important radical scavenger that prevents cell membrane ox-
idation and injury caused by reactive oxygen species. Moreover, this vitamin was also
demonstrated to play an important role as anti-cancer modulator [8]. Specifically, vitamin
C was shown to induce toxicity in selective oncogene-driven cancers and to slow down
tumour growth in animal models [35,36]. We have shown that F. prausnitzii is able to
use vitamin B2 (or riboflavin) as a redox mediator for extracellular electron transfer [9].
Considering the beneficial properties of F. prausnitzii as a butyrate producer, increased
amounts of this bacterium may be beneficial in the prevention of mucositis. In a study
performed by Xuan et al., 2013 human embryonic lung fibroblasts (Helf cells) were irra-
diated and then incubated with different concentrations of riboflavin laureate and their
proliferative properties were investigated. Results show that when higher concentrations
of this compound are added to the cultures, proliferation rates increase significantly sug-
gesting that on a cellular level, riboflavin laureate can enhance cell proliferation in both
oral and gastrointestinal mucositis [37]. In a prospective clinical study by von Martels et al.,
2019 vitamin B2 supplementation in Crohn’s disease patients resulted in reduced systemic
oxidative stress and clinical symptoms, suggesting that this vitamin has the capability to
improve inflammatory conditions. However, the mechanism was not via the modulation
of the microbiome, since this did not change upon vitamin B2 supplementation.
In the present study, we started by investigating the effects of both vitamins C and
B2, alone or in combination, on the in vitro growth of several bacterial strains intrinsically
associated with intestinal inflammation [21,24,25,27,38]. Our results show that, contrarily
to the reduction that is usually observed during chemotherapy-induced mucositis, vitamin
supplementation under oxidative conditions enhanced the growth of B. coccoides and R.
intestinalis. Moreover, no significant differences were observed on the growth of E. coli,
suggesting that prophylactic treatment with vitamins can restore beneficial bacteria in a
dysbiotic situation. These promising results led us to investigate the prophylactic potential
of these vitamins in vivo.
Here, we show that vitamin C does not profoundly modulate the gut microbiota dur-
ing the course of MTX-induced mucositis in rats, however it did influence the abundance
of specific microbes including in Lactobacillaceae, Enterobactereaceae, L. johnsonii and E. coli.
Despite the lack of microbial impact, vitamin C was able to lessen MTX-induced weight
loss and promote food intake in peak mucositis, albeit the benefits were mild. This suggests
that the documented benefits of vitamin C are most likely due to their immunomodu-
latory properties, comparable to those reported by Al-asmari et al., 2015 in which daily
administration of vitamin C (500 mg/kg) following 5-FU led to a significant reduction of
NF-κB activation [8]. The limited benefits of vitamin C also suggest that this approach is
not sufficient in mucositis control, or alternatively the schedule of intervention was not
sufficient to provide optimal mucosal protection. Studies have suggested a link between the
increased amount of Enterobacteriaceae in the gut and the development of gut inflammation
is several human diseases [39]. The increase in the relative amount of Enterobacteriaceae in
the MTX+VitC group could therefore explain the lack of a more effective anti-inflammatory
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response from vitamin C. This finding is in contrast to those by Verghese et al., 2017 who
demonstrated that vitamin C is able to prevent, in a dose-dependent manner, the in vitro
growth of bacteria such as E. coli [40].
Given the severity of bone marrow suppression that MTX causes and risk of blood
stream infection, this finding warrants further investigation and emphasizes the need to
rigorously assess the safety of such vitamin interventions for mucositis prevention.
Vitamin B2 is a water-soluble vitamin with anti-inflammatory and anti-oxidative
properties. Moreover, it has been shown that this vitamin is essential for the growth of
butyrate-producing bacteria such as F. prausnitzii that uses for extracellular electron shut-
tling, allowing the bacteria to grow under oxidative conditions [9]. In contrast to vitamin
C, vitamin B2 was unable to induce any clinical benefits to MTX-treated rats, and in fact
worsened mucositis outcomes in some instances, preventing completion of this experimen-
tal group. Its effects on the microbiota were also negligible, despite our in vitro studies
supporting beneficial impacts on microbial growth. The disparity between our in vitro
and in vivo findings is challenging to dissect, however we hypothesize that the in vitro
benefits were likely the result of the anti-oxidant properties of both vitamins, which in turn
allowed the bacteria to grow under stress conditions. For example, it is known that vitamin
B2 can act as an electron shuttle in anaerobic bacteria, thus facilitating respiration that
yields more energy for growth and reduces the environment [9]. Interestingly, in contrast
to our results, Levit et al., 2018 showed that administration of a riboflavin-producing strain
Lactobacillus plantarum to 5-FU-treated mice had a protective effect against chemotherapy-
induced mucositis, characterized by lower diarrhea scores, preserved mucosal architecture
and maintained of crypt length [41,42]. We hypothesize that, when translated in vivo,
vitamin B2 effects are insufficient to overcome the intensity of injury caused by MTX and
the hostility of the luminal micro-environment. This is supported by a study by Anandam
et al., 2018 who showed that prolonged exposure to pro-inflammatory cytokines such as
tumour necrosis factor (TNF) can inhibit intestinal uptake of vitamin B2. This is due to the
suppression of the expression of the apical vitamin B2 uptake system- hRFVT-3, a vitamin
B2 transporter. In line with these results, we suggest that vitamin B2 did not exert any
kind of beneficial effect due to the exacerbated inflammation caused by MTX. According
to several studies, TNF is highly expressed during the most severe phase of mucositis.
This increased expression might therefore explain the lack of response to this specific dose
of vitamin B2 tested.
While there are plausible explanations for the lack of efficacy demonstrated for pro-
phylactic vitamin supplementation, there are several limitations in our study that warrant
recognition. To ensure translation of our findings and integration into clinical practice,
we employed a short prophylactic regimen, with vitamins administered one day prior
to MTX treatment. It is possible that either the amount of vitamins reaching the small
intestine was not sufficient to overcome MTX effects or that there was not sufficient time to
allow for microbial modulation, with effects only mildly evident at day 10. If indeed the
perceived benefits of vitamins are due to their immunomodulatory effects, administration
may be optimized to promote restoration of the mucosa in the recovery phase by the
recruitment of gut homing reparative lymphocytes (day 7–10). However, these are mere
speculations based on previous observations, since we did not access the anti-inflammatory
properties of these vitamins and, in the case of vitamin B2 supplementation, the number of
animals in the MTX+VitB2 group was considerably low. Therefore, further studies need
to be performed in order to investigate the full potential of these vitamins in the set of
chemotherapy-induced mucositis.
5. Conclusions
In conclusion, the findings of the present study provide critical evidence regarding the
challenges in using vitamins to prevent or control MTX-induced mucositis. We have shown
the potential of vitamin C in ameliorating mucositis symptoms, yet its effect on the microbiota
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requires further optimization for improved mucosal protection. Future research on vitamins
in mucositis should consider extended prophylaxis to improve magnitude of effect.
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